Linda M S Resar

List of Publications by Citations

88 papers	3,012 citations	30 h-index	54 g-index
95 ext. papers	3,418 ext. citations	4.6 avg, IF	4.85 L-index

#	Paper	IF	Citations
88	Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures. *Cell Research*, **2011**, 21, 518-29	24.7	363
87	Function of the c-Myc oncogenic transcription factor. *Experimental Cell Research*, **1999**, 253, 63-77	4.2	297
86	HMG-I/Y, a new c-Myc target gene and potential oncogene. *Molecular and Cellular Biology*, **2000**, 20, 5490-502	4.8	159
85	Exchange blood transfusion compared with simple transfusion for first overt stroke is associated with a lower risk of subsequent stroke: a retrospective cohort study of 137 children with sickle cell anemia. *Journal of Pediatrics*, **2006**, 149, 710-2	3.6	113
84	HMGA2 participates in transformation in human lung cancer. *Molecular Cancer Research*, **2008**, 6, 743-50	6.6	107
83	The HMG-I oncogene causes highly penetrant, aggressive lymphoid malignancy in transgenic mice and is overexpressed in human leukemia. *Cancer Research*, **2004**, 64, 3371-5	10.1	102
82	The high mobility group A1 gene: transforming inflammatory signals into cancer?. *Cancer Research*, **2010**, 70, 436-9	10.1	88
81	HMGA1: a master regulator of tumor progression in triple-negative breast cancer cells. *PLoS ONE*, **2013**, 8, e63419	3.7	88
80	A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily. *Cell Systems*, **2018**, 7, 422-437.e7	10.6	85
79	The high-mobility group A1a/signal transducer and activator of transcription-3 axis: an achilles heel for hematopoietic malignancies?. *Cancer Research*, **2008**, 68, 10121-7	10.1	82
78	HMGA1 induces intestinal polyposis in transgenic mice and drives tumor progression and stem cell properties in colon cancer cells. *PLoS ONE*, **2012**, 7, e30034	3.7	81
77	A novel method of data analysis for utilization of red blood cell transfusion. *Transfusion*, **2013**, 53, 3052-9	2.9	73
76	HMGA1 reprograms somatic cells into pluripotent stem cells by inducing stem cell transcriptional networks. *PLoS ONE*, **2012**, 7, e48533	3.7	69
75	HMGA1 correlates with advanced tumor grade and decreased survival in pancreatic ductal adenocarcinoma. *Modern Pathology*, **2010**, 23, 98-104	9.8	62
74	HMGA1 drives stem cell, inflammatory pathway, and cell cycle progression genes during lymphoid tumorigenesis. *BMC Genomics*, **2011**, 12, 549	4.5	61
73	The high-mobility group A1 gene up-regulates cyclooxygenase 2 expression in uterine tumorigenesis. *Cancer Research*, **2007**, 67, 3998-4004	10.1	61
72	Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. *Cancer Research*, **2019**, 79, 4326-4330	10.1	57

71	High mobility group A1 and cancer: potential biomarker and therapeutic target. *Histology and Histopathology*, **2012**, 27, 567-79	1.4	57
70	Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large-cell lung cancer. *Molecular Cancer Research*, **2009**, 7, 1803-12	6.6	55
69	HMG-I/Y in human breast cancer cell lines. *Breast Cancer Research and Treatment*, **2002**, 71, 181-91	4.4	52
68	High mobility group protein HMGI(Y) enhances tumor cell growth, invasion, and matrix metalloproteinase-2 expression in prostate cancer cells. *Prostate*, **2004**, 60, 160-7	4.2	46
67	Dominant-negative c-Jun (TAM67) target genes: HMGA1 is required for tumor promoter-induced transformation. *Oncogene*, **2004**, 23, 4466-76	9.2	44
66	Neuropsychologic Deficits in Children with Sickle Cell Disease and Cerebral Infarction: Role of Lesion Site and Volume. *Child Neuropsychology*, **1999**, 5, 92-103	2.7	43
65	Risk-adjusted clinical outcomes in patients enrolled in a bloodless program. *Transfusion*, **2014**, 54, 2668-77	2.9	41
64	Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia. *Leukemia and Lymphoma*, **2011**, 52, 1999-2006	1.9	38
63	HMGA1 amplifies Wnt signalling and expands the intestinal stem cell compartment and Paneth cell niche. *Nature Communications*, **2017**, 8, 15008	17.4	34
62	Characterizing metabolic changes in human colorectal cancer. *Analytical and Bioanalytical Chemistry* , **2015**, 407, 4581-95	4.4	34
61	Efficacy of education followed by computerized provider order entry with clinician decision support to reduce red blood cell utilization. *Transfusion*, **2015**, 55, 1628-36	2.9	34
60	How I treat priapism. *Blood*, **2015**, 125, 3551-8	2.2	32
59	Induction of fetal hemoglobin synthesis in children with sickle cell anemia on low-dose oral sodium phenylbutyrate therapy. *Journal of Pediatric Hematology/Oncology*, **2002**, 24, 737-41	1.2	30
58	Sequence and analysis of the murine Hmgiy (Hmga1) gene locus. *Gene*, **2001**, 271, 51-8	3.8	29
57	Cyclooxygenase inhibitors block uterine tumorigenesis in HMGA1a transgenic mice and human xenografts. *Molecular Cancer Therapeutics*, **2008**, 7, 2090-5	6.1	28
56	The high mobility group A1 molecular switch: turning on cancer - can we turn it off?. *Expert Opinion on Therapeutic Targets*, **2014**, 18, 541-53	6.4	27
55	The HMGA1-COX-2 axis: a key molecular pathway and potential target in pancreatic adenocarcinoma. *Pancreatology*, **2012**, 12, 372-9	3.8	27
54	HMG-I/Y Is a c-Jun/Activator Protein-1 Target Gene and Is Necessary for c-Jun–Induced Anchorage-Independent Growth in Rat1a Cells. *Molecular Cancer Research*, **2004**, 2, 305-314	6.6	26

53	Lessons from the Crypt: HMGA1-Amping up Wnt for Stem Cells and Tumor Progression. *Cancer Research*, **2018**, 78, 1890-1897	10.1	24
52	HMG-I/Y is a c-Jun/activator protein-1 target gene and is necessary for c-Jun-induced anchorage-independent growth in Rat1a cells. *Molecular Cancer Research*, **2004**, 2, 305-14	6.6	24
51	HMGA1 overexpression correlates with relapse in childhood B-lineage acute lymphoblastic leukemia. *Leukemia and Lymphoma*, **2013**, 54, 2565-7	1.9	23
50	HMGA1 drives metabolic reprogramming of intestinal epithelium during hyperproliferation, polyposis, and colorectal carcinogenesis. *Journal of Proteome Research*, **2015**, 14, 1420-31	5.6	23
49	Bloodless medicine: what to do when you can't transfuse. *Hematology American Society of Hematology Education Program*, **2014**, 2014, 553-8	3.1	21
48	Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden. *Blood Advances*, **2020**, 4, 2567-2576	7.8	19
47	Bloodless medicine: current strategies and emerging treatment paradigms. *Transfusion*, **2016**, 56, 2637-2647	2.9	19
46	Inactivation of the Cdkn2a locus cooperates with HMGA1 to drive T-cell leukemogenesis. *Leukemia and Lymphoma*, **2013**, 54, 1762-8	1.9	17
45	AKNA: another AT-hook transcription factor "hooking-up" with inflammation. *Cell Research*, **2011**, 21, 1528-30	24.7	17
44	Hydroxyurea therapy for priapism prevention and erectile function recovery in sickle cell disease: a case report and review of the literature. *International Urology and Nephrology*, **2014**, 46, 1733-1736	2.3	16
43	Pulsed-dosing with oral sodium phenylbutyrate increases hemoglobin F in a patient with sickle cell anemia. *Pediatric Blood and Cancer*, **2008**, 50, 357-9	3	15
42	Hitting the bull's eye: targeting HMGA1 in cancer stem cells. *Expert Review of Anticancer Therapy*, **2014**, 14, 23-30	3.5	14
41	Hemoglobin thresholds for transfusion in pediatric patients at a large academic health center. *Transfusion*, **2015**, 55, 2890-7	2.9	13
40	Nanoparticle delivery of inhibitory signal transducer and activator of transcription 3 G-quartet oligonucleotides blocks tumor growth in HMGA1 transgenic model of T-cell leukemia. *Leukemia and Lymphoma*, **2014**, 55, 1194-7	1.9	12
39	Ghosal hematodiaphyseal dysplasia: a rare cause of a myelophthisic anemia. *Pediatric Blood and Cancer*, **2010**, 55, 1187-90	3	12
38	Patent foramen ovale in patients with sickle cell disease and stroke: case presentations and review of the literature. *Case Reports in Hematology*, **2013**, 2013, 516705	0.7	11
37	STAT3 inhibitor has potent antitumor activity in B-lineage acute lymphoblastic leukemia cells overexpressing the high mobility group A1 (HMGA1)-STAT3 pathway. *Leukemia and Lymphoma*, **2016**, 57, 2681-4	1.9	10
36	PBOV1 as a potential biomarker for more advanced prostate cancer based on protein and digital histomorphometric analysis. *Prostate*, **2018**, 78, 547-559	4.2	8

35	Fecal Metabolome in Hmga1 Transgenic Mice with Polyposis: Evidence for Potential Screen for Early Detection of Precursor Lesions in Colorectal Cancer. *Journal of Proteome Research*, **2016**, 15, 4176-4187	5.6	7
34	Preoperative treatment of anemia and outcomes in surgical Jehovah's Witness patients. *American Journal of Hematology*, **2019**, 94, E55-E58	7.1	6
33	Symptomatic Avascular Necrosis: An Understudied Risk Factor for Acute Care Utilization by Patients with SCD. *Southern Medical Journal*, **2016**, 109, 519-24	0.6	5
32	Transcriptomic analysis in pediatric spinal ependymoma reveals distinct molecular signatures. *Oncotarget*, **2017**, 8, 115570-115581	3.3	5
31	Approaches to Bloodless Surgery for Oncology Patients. *Hematology/Oncology Clinics of North America*, **2019**, 33, 857-871	3.1	5
30	Greater anemia tolerance among hospitalized females compared to males. *Transfusion*, **2019**, 59, 2551-2558	2.9	4
29	Low dose, oral epsilon aminocaproic acid for renal papillary necrosis and massive hemorrhage in hemoglobin SC disease. *Pediatric Blood and Cancer*, **2010**, 54, 148-50	3	4
28	High mobility group A1 (HMGA1) protein and gene expression correlate with ER-negativity and poor outcomes in breast cancer. *Breast Cancer Research and Treatment*, **2020**, 179, 25-35	4.4	4
27	Genetic Engineering of Primary Mouse Intestinal Organoids Using Magnetic Nanoparticle Transduction Viral Vectors for Frozen Sectioning. *Journal of Visualized Experiments*, **2019**,	1.6	3
26	Conditional reprogramming culture conditions facilitate growth of lower-grade glioma models. *Neuro-Oncology*, **2021**, 23, 770-782	1	3
25	Patent foramen ovale in adults with sickle cell disease and stroke. *American Journal of Hematology*, **2016**, 91, E358-60	7.1	3
24	Hitting the bull□ eye: targeting HMGA1 in cancer stem cells. *Expert Review of Anticancer Therapy*,1-8	3.5	2
23	Integrative molecular characterization of pediatric spinal ependymoma: the UK Children's Cancer and Leukaemia Group study. *Neuro-Oncology Advances*, **2021**, 3, vdab043	0.9	2
22	Doubling up on function: dual-specificity tyrosine-regulated kinase 1A (DYRK1A) in B cell acute lymphoblastic leukemia. *Journal of Clinical Investigation*, **2021**, 131,	15.9	2
21	More common than you think: common variable immune deficiency. *Case Reports in Hematology*, **2013**, 2013, 153767	0.7	1
20	Flavopiridol Down-Regulates Genes Involved in Cell Cycle Regulation and Tumor Progression in Adults with Refractory or Poor-Risk Acute Leukemia.. *Blood*, **2008**, 112, 953-953	2.2	1
19	High Mobility Group A1 (HMGA1) Chromatin Remodeling Protein Mediates Crosstalk Between Acute Myeloid Leukemia Blasts & the Tumor Microenvironment. *Blood*, **2014**, 124, 3564-3564	2.2	1
18	High Mobility Group A1 Chromatin Remodeling Protein Regulates Self-Renewal, Niche Formation, and Regenerative Function in Adult Stem Cells through Wnt/□Catenin Signaling. *Blood*, **2016**, 128, 2647-2647	2.2	1

17	Perioperative Management of Patients for Whom Transfusion Is Not an Option. *Anesthesiology*, **2021**, 134, 939-948	4.3	1
16	Hmga1 deficiency: "SAC-King" the SAC genes to incite chromosomal instability. *Cell Cycle*, **2017**, 16, 17-18	4.7	0
15	The HMGA1a-STAT3 axis: an Achilles Heel for Hematopoietic Malignancies Overexpressing HMGA1a?. *Blood*, **2008**, 112, 3810-3810	2.2	0
14	Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia. *Pediatric Blood and Cancer*, **2021**, 68, e28888	3	0
13	The High Mobility Group A1 Chromatin Regulator Drives Immune Evasion during MPN Progression By Repressing Genes Involved in Antigen Presentation and Immune Attack. *Blood*, **2021**, 138, 2546-2546	2.2	
12	STAT3: A Direct HMGA1 Gene Target Important in Lymphoid Malignancy.. *Blood*, **2006**, 108, 2222-2222	2.2	
11	High Mobility Group A1 Chromatin Remodeling Proteins Amplify Inflammatory Networks to Drive Leukemic Transformation in Chronic Myeloproliferative Neoplasia in Humans and JAK2V617F Transgenic Mouse Models. *Blood*, **2018**, 132, 102-102	2.2	
10	The High Mobility Group A1 Chromatin Regulator Is Required for Pathologic Megakaryocyte Development and Progression to Myelofibrosis in JAK2V617F Murine Models. *Blood*, **2019**, 134, 472-472	2.2	
9	Patent Foramen Ovale in Adult Patients with Sickle Cell Disease and Stroke. *Blood*, **2014**, 124, 4084-4084	2.2	
8	Essential Thrombocytosis: Redefinition in the Genomic Era. *Blood*, **2014**, 124, 3205-3205	2.2	
7	Avascular Necrosis: An Understudied Risk Factor for Acute Care Utilization By Patients with Sickle Cell Disease. *Blood*, **2014**, 124, 2709-2709	2.2	
6	A Novel Feed-Forward Loop Involving the High Mobility Group A1 (HMGA1) Chromatin Remodeling Protein and cMYC in Acute Myeloid Leukemia Is Targeted By JQ1. *Blood*, **2015**, 126, 2466-2466	2.2	
5	High Mobility Group A1/2 Chromatin Remodeling Proteins Associate with Polycythemia Vera Transformation to Acute Leukemia in Humans and a JAK2 V617F Transgenic Mouse Model. *Blood*, **2016**, 128, 1958-1958	2.2	
4	Inactivation of the INK4A/ARF (CDKN2) locus Cooperates with HMGA1 in T-Cell Leukemogenesis.. *Blood*, **2009**, 114, 3969-3969	2.2	
3	HMGA1 Drives Inflammatory Pathways, Cell Cycle Progression, and Embryonic Stem Cell Genes During Leukemic Transformation. *Blood*, **2011**, 118, 1371-1371	2.2	
2	Polycythemia Vera: Redefinition in the Genomic Era. *Blood*, **2012**, 120, 1754-1754	2.2	
1	HMGA1, a Factor Enriched in Hematopoietic Stem Cells, Embryonic Stem Cells, and Hematologic Malignancy, Enhances Cellular Reprogramming to a Pluripotent Stem-Like Cell.. *Blood*, **2012**, 120, 2323-2323	2.2	